Progyny (NASDAQ:PGNY) Shares Climb 2.9% – Still a Buy?

Progyny, Inc. (NASDAQ:PGNY)’s stock price shot up 2.9% on Wednesday. The company traded as high as $26.59 and last traded at $26.67. Approximately 56,585 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 1,393,381 shares. The stock had previously closed at $25.91.

Analysts Set New Price Targets

Several brokerages have recently weighed in on PGNY. Wells Fargo & Company began coverage on shares of Progyny in a research report on Wednesday, September 30th. They issued an “overweight” rating and a $37.00 price target for the company. Jefferies Financial Group set a $33.00 price objective on shares of Progyny in a report on Tuesday, September 8th. Zacks Research raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 8th. Citizens Jmp boosted their price objective on shares of Progyny from $31.00 to $33.00 and gave the stock a “market outperform” rating in a research note on Tuesday, September 8th. Finally, Citigroup restated an “outperform” rating on shares of Progyny in a report on Tuesday, September 8th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $34.36.

Progyny Stock Performance

The company has a 50 day simple moving average of $26.77 and a two-hundred day simple moving average of $25.10. The firm has a market cap of $2.14 billion, a PE ratio of 30.25, a P/E/G ratio of 1.90 and a beta of 1.02.

Progyny (NASDAQ:PGNY) last released its earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The firm had revenue of $350.51 million during the quarter, compared to the consensus estimate of $349.05 million. During the same quarter in the previous year, the company posted $0.19 earnings per share. The company’s revenue was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, research analysts predict that Progyny, Inc. will post 1.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Progyny news, Director Kevin K. Gordon sold 11,500 shares of the company’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $27.94, for a total value of $321,310.00. Following the sale, the director directly owned 6,792 shares of the company’s stock, valued at approximately $189,768.48. This represents a 62.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Allison Swartz sold 3,903 shares of the stock in a transaction dated Wednesday, September 23rd. The stock was sold at an average price of $26.10, for a total value of $101,868.30. Following the sale, the executive vice president directly owned 75,816 shares in the company, valued at $1,978,797.60. This represents a 4.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.90% of the stock is owned by corporate insiders.

Institutional Trading of Progyny

A number of hedge funds have recently modified their holdings of PGNY. Toth Financial Advisory Corp grew its stake in shares of Progyny by 21.3% during the 3rd quarter. Toth Financial Advisory Corp now owns 2,735 shares of the company’s stock worth $69,000 after purchasing an additional 480 shares during the period. WINTON GROUP Ltd grew its position in Progyny by 266.7% during the second quarter. WINTON GROUP Ltd now owns 251,834 shares of the company’s stock valued at $7,260,000 after buying an additional 183,163 shares during the period. Engineers Gate Manager LP increased its holdings in Progyny by 5.6% in the second quarter. Engineers Gate Manager LP now owns 152,757 shares of the company’s stock valued at $4,404,000 after buying an additional 8,156 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in Progyny in the second quarter valued at $74,000. Finally, IFP Advisors Inc raised its position in shares of Progyny by 376.0% in the second quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock worth $57,000 after acquiring an additional 1,549 shares during the period. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc (NASDAQ: PGNY) is a fertility and family-building benefits company that helps employers provide reproductive health services to their employees. Its platform is designed to support individuals and families navigating fertility treatment, preservation, adoption, surrogacy and related family-building needs.

The company offers an integrated benefits solution that combines personalized care navigation with access to a network of fertility specialists and treatment providers. Progyny also provides pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.